Pharma Mar SA (PHMMF)
94.60
0.00 (0.00%)
USD |
OTCM |
Sep 18, 16:00
Pharma Mar Cash from Investing (Quarterly) : -37.88M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -37.88M |
| March 31, 2026 | 33.95M |
| December 31, 2025 | -67.73M |
| September 30, 2025 | 14.54M |
| June 30, 2025 | -29.47M |
| March 31, 2025 | 11.91M |
| December 31, 2024 | 22.38M |
| September 30, 2024 | 1.018M |
| June 30, 2024 | 7.200M |
| March 31, 2024 | -29.28M |
| December 31, 2023 | 1.790M |
| September 30, 2023 | 6.718M |
| June 30, 2023 | -22.14M |
| March 31, 2023 | -32.77M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -10.35M |
| March 31, 2022 | 2.892M |
| December 31, 2021 | -12.99M |
| September 30, 2021 | -3.005M |
| June 30, 2021 | 39.61M |
| March 31, 2021 | -1.654M |
| December 31, 2020 | 4.331M |
| September 30, 2020 | -100.17M |
| June 30, 2020 | -22.41M |
| Date | Value |
|---|---|
| March 31, 2020 | -18.28M |
| December 31, 2019 | -3.470M |
| September 30, 2019 | -0.6482M |
| June 30, 2019 | 39.42M |
| March 31, 2019 | 0.7948M |
| December 31, 2018 | -1.286M |
| September 30, 2018 | 24.90M |
| June 30, 2018 | 3.167M |
| March 31, 2018 | -0.8345M |
| December 31, 2017 | 10.72M |
| September 30, 2017 | 2.657M |
| June 30, 2017 | 5.847M |
| March 31, 2017 | -11.39M |
| December 31, 2016 | 3.002M |
| September 30, 2016 | 7.112M |
| June 30, 2016 | 5.672M |
| March 31, 2016 | -0.4432M |
| December 31, 2015 | -33.46M |
| September 30, 2015 | -3.801M |
| June 30, 2015 | 5.882M |
| March 31, 2015 | 0.3878M |
| December 31, 2014 | -17.47M |
| September 30, 2014 | -1.263M |
| June 30, 2014 | 0.4717M |
| March 31, 2014 | -10.57M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Oryzon Genomics SA | -- |
| Grifols SA | -156.60M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alkermes Plc | -2.411M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.848M |
| Cash from Financing (Quarterly) | -0.0493M |
| Free Cash Flow | 62.89M |
| Free Cash Flow Per Share (Quarterly) | 0.0679 |
| Free Cash Flow to Equity (Quarterly) | 3.541M |
| Free Cash Flow to Firm (Quarterly) | 1.177M |
| Free Cash Flow Yield | 3.82% |